Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Somnath Mukherjee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7202-0698; OpenAlex author ID A5101715881. Sources: OpenAlex.

Their work

Papers
35 (first author 5, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
93
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 6 papers · 2017: 3 papers · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: 7 papers · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers

Papers 35

  1. Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK. First author DOI 10.1016/j.clon.2024.05.012↗
  2. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/ra… Co-author DOI 10.1016/j.ejca.2024.114236↗
  3. Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized therapy. Co-author DOI 10.1126/sciadv.adm9071↗
  4. Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity. Co-author DOI 10.7554/elife.92672↗
  5. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  6. Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expans… Last author DOI 10.1136/bmjopen-2022-068906↗
  7. Predicting Early Disease Recurrence of Pancreatic Cancer following Surgery: Determining the Role of NUDT15 as a Prognostic Biomarker. Co-author DOI 10.3390/curroncol29040206↗
  8. Stereotactic Ablative Body Radiotherapy for Locally Advanced Unresectable Pancreatic Cancer: Current Views of the Public and Professionals. Co-author DOI 10.1016/j.clon.2020.10.015↗
  9. ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2020.07.052↗
  10. SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.radonc.2020.11.007↗
  11. Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. Last author DOI 10.1038/s41416-020-01120-z↗
  12. Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". Last author DOI 10.1038/s41416-020-01133-8↗
  13. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-021-00192-1↗
  14. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. Co-author DOI 10.1053/j.gastro.2021.04.044↗
  15. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Last author DOI 10.1038/s41416-020-0980-x↗
  16. Early Detection in a Mouse Model of Pancreatic Cancer by Imaging DNA Damage Response Signaling. Co-author DOI 10.2967/jnumed.119.234708↗
  17. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for lo… Last author DOI 10.1186/s12885-019-5307-z↗
  18. Translational molecular imaging in exocrine pancreatic cancer. Co-author DOI 10.1007/s00259-018-4146-5↗
  19. Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.clon.2018.02.067↗
  20. Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. Co-author DOI 10.1016/j.pan.2018.09.012↗
  21. Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after … First author DOI 10.1016/j.clon.2017.01.038↗
  22. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pa… Last author DOI 10.1038/bjc.2017.95↗
  23. 89Zr-anti-γH2AX-TAT but not 18F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-0664↗
  24. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.03.021↗
  25. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial. Last author DOI 10.1016/j.radonc.2016.07.002↗
  26. Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.08.001↗
  27. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. Co-author DOI 10.1186/s12885-016-2765-4↗
  28. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.5561↗
  29. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.6770↗
  30. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Co-author DOI 10.1016/j.bbcan.2014.12.001↗
  31. Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer. First author DOI 10.1016/j.ijrobp.2015.08.026↗
  32. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP tr… Last author DOI 10.1016/j.radonc.2015.08.026↗
  33. Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. First author DOI 10.1016/j.clon.2014.06.002↗
  34. Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer. First author DOI 10.1186/1748-717x-9-146↗
  35. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Co-author DOI 10.1016/s1470-2045(13)70021-4↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. M. Hawkins · 12 shared papers, 2014–2024 · strength 1.08
  2. Eric E. O’Neill · 9 shared papers, 2016–2024 · strength 1.03
  3. Tim Maughan · 10 shared papers, 2013–2024 · strength 0.99
  4. Ganesh Radhakrishna · 9 shared papers, 2013–2024 · strength 0.84
  5. Chris N Hurt · 10 shared papers, 2013–2024 · strength 0.79
  6. D. Holyoake · 7 shared papers, 2016–2024 · strength 0.68
  7. Frances W. Willenbrock · 4 shared papers, 2021–2024 · strength 0.63
  8. Daniel Llwyd Hughes · 4 shared papers, 2021–2024 · strength 0.63
  9. James S. Good · 4 shared papers, 2020–2024 · strength 0.55
  10. Pippa G. Corrie · 5 shared papers, 2018–2024 · strength 0.49
  11. Christopher Mark Jones · 4 shared papers, 2020–2024 · strength 0.47
  12. Derek B. Grose · 5 shared papers, 2016–2021 · strength 0.43
  13. Simei Go · 2 shared papers, 2024 · strength 0.40
  14. Killian Nugent · 2 shared papers, 2023–2024 · strength 0.36
  15. S. Teoh · 2 shared papers, 2023–2024 · strength 0.36
  16. Mike Partridge · 5 shared papers, 2014–2018 · strength 0.34
  17. Katharine L. Aitken · 3 shared papers, 2020–2021 · strength 0.33
  18. Emmanouil Fokas · 6 shared papers, 2015–2016 · strength 0.32
  19. Thomas Baptist Brunner · 4 shared papers, 2014–2021 · strength 0.32
  20. Michael Eyres · 2 shared papers, 2021–2024 · strength 0.31
  21. Paula Ghaneh · 3 shared papers, 2020–2023 · strength 0.31
  22. Daniel H. Palmer · 3 shared papers, 2020–2023 · strength 0.31
  23. Juan W. Valle · 3 shared papers, 2020–2023 · strength 0.31
  24. Harpreet Singh Wasan · 3 shared papers, 2013–2024 · strength 0.31
  25. Simone Lanfredini · 2 shared papers, 2021–2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.